<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00495183</url>
  </required_header>
  <id_info>
    <org_study_id>CAF-MT</org_study_id>
    <secondary_id>eudraCT 2005-06-01</secondary_id>
    <nct_id>NCT00495183</nct_id>
  </id_info>
  <brief_title>Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence</brief_title>
  <official_title>Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the efficacy of caffeine compared to placebo as a
      maintenance treatment for cocaine dependence. Caffeine potentiation with biperiden will be
      also studied.

      Ninety patients with snorted/sniffed cocaine dependence will be randomized to receive
      caffeine (300 - 1200 mg t.i.d.) plus biperidene (8 mg b.i.d.) caffeine (300 - 1200 mg t.i.d.)
      with placebo or placebo during 10 days in an in-hospital setting.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">July 2010</completion_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival</measure>
    <time_frame>22 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>cocaine use</measure>
    <time_frame>22 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>caffeine + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>caffeine + biperiden</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo+placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caffeine</intervention_name>
    <description>caffeine from 300 to 1200 mg/d or 15 mg/kg/d, divided in 3 doses per day.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Durvitan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biperiden</intervention_name>
    <description>Biperiden 2-4 mg/d, divided in 2 doses per day.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Akineton</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of cocaine dependence, according to DSM-IV-TR criteria

          -  age between 18 and 60 years

          -  current cocaine use, confirmed by a positive urine drug screen for cocaine the week
             prior to admission.

          -  demonstrated capacity to grant informed consent and sign the pertinent informed
             consent form.

          -  place of residence compatible with attendance at the center.

          -  for women, willingness to use effective contraceptive measures during the study.

        Exclusion Criteria:

          -  diagnosis of a severe medical disorder that could interfere with the study

          -  presence of an organic pathology for which methylxanthines or biperidene
             administration is contraindicated

          -  serum liver transaminase levels 3 times higher than normal values

          -  pregnancy and breast-feeding

          -  neuroleptic medication treatment in the past 6 weeks

          -  current treatment, or anticipation that the patient may need to initiate treatment
             during the study, with drugs that may interact with study medication.

          -  current diagnosis of a major mental disorder.

          -  awareness of a situation that could prevent the patient's participation in the study
             (e.g. serving a sentence)

          -  current participation in another research project.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miquel Casas, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari Vall d'Hebron Barcelona, Catalonia, Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miquel Casas, Prof.</last_name>
    <phone>0034 93 489 42 94</phone>
    <email>mcasas@vhebron.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xavier Castells, MD</last_name>
    <phone>0034 93 489 42 94</phone>
    <email>xcc@icf.uab.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miquel Casas, Prof</last_name>
      <phone>0034 93 489 42 94</phone>
      <email>mcasas@vhebron.net</email>
    </contact>
    <contact_backup>
      <last_name>Xavier Castells, MD</last_name>
      <email>xcc@icf.uab.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos Roncero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Castells Xavier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gonzalvo Begoña, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2007</study_first_submitted>
  <study_first_submitted_qc>June 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2007</study_first_posted>
  <last_update_submitted>May 26, 2010</last_update_submitted>
  <last_update_submitted_qc>May 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Miguel Casas Brugué</name_title>
    <organization>Servei de Psiquiatria. Hospital Universitari Vall d'Hebron</organization>
  </responsible_party>
  <keyword>cocaine dependence</keyword>
  <keyword>cocaine use</keyword>
  <keyword>CNS stimulants</keyword>
  <keyword>caffeine</keyword>
  <keyword>biperiden</keyword>
  <keyword>placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Biperiden</mesh_term>
    <mesh_term>Biperiden lactate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

